XyloCor bags $23M to expand heart disease gene therapy R&D

XyloCor Therapeutics has raised $22.6 million to study a gene therapy designed to deliver VEGF to heart cells. The financing, which swells the series A to $41.9 million, positions XyloCor to study its lead candidate in patients undergoing coronary artery bypass graft surgery (CABG).